Drug intelligence / Profile preview

cefpodoxime proxetil

Development stage
Approved
Lead developer
Rishab Health Care
Modality
Small Molecules
Administration
Oral
01

Overview

HIPODOX is a branded generic formulation of **cefpodoxime proxetil**, a third-generation cephalosporin antibiotic. It is developed and manufactured by Rishab Health Care for the Indian market, available in oral dosage forms including 100 mg and 200 mg tablets and a dry syrup formulation for pediatric use. Cefpodoxime proxetil is an orally active prodrug that is hydrolyzed in the gastrointestinal tract to its active metabolite, cefpodoxime. It exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). The drug is indicated for the treatment of various mild to moderate infections caused by susceptible strains of microorganisms, including acute otitis media, pharyngitis, tonsillitis, community-acquired pneumonia, and uncomplicated urinary tract infections.

Brand names
HIPODOXHIPODOX-100HIPODOX100HIPODOX 100HIPODOX-200HIPODOX200HIPODOX 200
Other names
cefpodoxime
02

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on cefpodoxime proxetil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefpodoxime proxetil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call